AZD0530 difumarate - Saracatinib difumarate

Based on 20 reference(s) in Google Scholar 80 100 20

Axon 1456

CAS [893428-72-3]

MF C27H32ClN5O5.2C4H4O4
MW 774.17

Purity: 99%
Soluble in DMSO

AZD0530 difumarate

Description

An orally bioavailable tyrosine kinase inhibitor, specifically targeting Src and Abl, those kinases often overexpressed in chronic myeloid leukema cells. Optimal water-soluble form.

Saracatinib (as free base) is available as Axon 3284.

H Laurent et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 2006, 49, 6465.

YM Chang et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 1–11.

PM Gwanmesia et al. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. BMC Cancer 2009, 9, 53.

TP Green et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology 2009, 3(3), 248-261.

C Dulsat et al. Saracatinib. Drugs Fut. 2009, 34(2), 106.

Inhibitor of SRC and ABL tyrosine kinases

Chemical name

(5-Chloro-benzo[1,3]dioxol-4-yl)-[7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-5-(tetrahydro-pyran-4-yloxy)-quinazolin-4-yl]-amine (2E)-2-butenedioate (1:2)

Parent CAS No.

[379231-04-6]

Order

Size	Unit Price	Stock
5 mg	€70.00	In Stock
25 mg	€200.00	In Stock

Special Offers

Size	Unit Price	Stock
2 x 5 mg	€100.00	In Stock

Need more? Bulk Inquiry

Customer Support

Customer Services

About Axon Medchem

Contact Us

AZD0530 difumarate - Saracatinib difumarate

Description

Chemical name

Parent CAS No.

Customer Support

About Axon Medchem

Download Product Catalog

Follow Us

Customer Support

Customer Services

About Axon Medchem

Contact Us

AZD0530 difumarate - Saracatinib difumarate

Description

Chemical name

Parent CAS No.

Customer Support

About Axon Medchem

Download Product Catalog

Follow Us

Send us a message

Contact Us